TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01798472

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cemented hemiarthroplasty
Description: Patients aged 80 years and older operated with an cemented hemiarthroplasty. Fixation of the wedge-shaped, polished ChromCobalt steel femoral stem to host bone by use of PolyMetylMetAcrylat bone cement. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reverse hybrid total hip arthroplasty
Description: Patients aged 65 to 79 years operated with an uncemented femoral component combined with cemented acetabular cup. The femoral stem is fixed to the host bone by press-fit technique. We use a tapered, proximally hydroxyapatite coated, titanium stem. The acetabular cup is fixed to the host bone with bone cement. We use an all-polyethylene design. Bone cement consists of PolyMetylMetAcrylat.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cemented total hip arthroplasty
Description: Patients aged 65 to 79 years operated with a cemented femoral stem combined with a cemented acetabular cup. Femoral and acetabular component are fixed to the host bone by use of bone cement. The femoral stem is a polished, wedge-shaped design made of ChromCobalt steel. The acetabular cup is fixed to the host bone with bone cement.The acetabular cup an all-polyethylene design. Bone cement consists of PolyMetAcrylat.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uncemented hemiarthroplasty
Description: Patients aged 80 years and older are randomized to uncemented hemiarthroplasty. Fixation of the tapered, proximally hydroxyapatite coated, titanium stem to the host bone by press-fit-technique. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel.
Study: NCT01061762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stick To It
Description: 3-counseling session adherence intervention tailored for people with poor literacy skills

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard medication adherence counseling
Description: 3 counseling sessions for adherence improvement derived from standard behavioral approaches.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Counseling
Description: 3-session of health improvement counseling to serve as an attention control.
Study: NCT00787527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolinza (vorinostat)
Description: Up to two 100 mg capsules of Vorinostat (dosage will vary from 100 mg orally (PO) twice daily (BID), 300 mg PO every evening and 200 mg PO BID with the starting dose at 300 mg PO every evening for the phase I trial) are to be administered orally twice daily (once in the morning and once in the evening, or if in the daily dosing cohort once in the evening) in repeated 21-day cycles consisting of 10 days dosing starting on days 5 through 14 followed by a 7-day rest period, during which no vorinostat will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m\^2 by vein over 1 hour on Day 1 of 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m\^2 by vein over 15 minutes on Day 1 of 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m\^2 by vein over 15 minutes on Day 1 of 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg tablets by mouth once a day on Days 1-5 of 21 day cycle
Study: NCT03331393

Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional

Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional
Study: NCT01728610

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic (Active high)
Description: Higher dose of probiotic supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic (Active low)
Description: Lower dose of probiotic supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00723489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Yellow Fever Vaccine (YFV-17D)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Yellow Fever Vaccine (YFV-17D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YFV-17D Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YFV-17D Placebo
Study: NCT02399189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-MT followed by auto-HSCT
Description: Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous stem cell transplantation: Carmustine 400mg/m2 d1; Thiotepa 5mg/kg q12h, d2-3.
Study: NCT01332747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: compressed tablet of safoof e muhazzil
Description: drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.~compressed into tablets of 1 gm each+ binders qs. dose is 5 tablets twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: atorvastatin 10 mgs once daily
Study: NCT00547521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abatacept
Description: solution, subcutaneous injection, 125 mg/kg, weekly, 106 days in short term; long term is open

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abatacept
Description: solution, subcutaneous injection, 125 mg/kg, weekly, 106 days in short term; long term is open

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Participants who were currently receiving methotrexate at a stable dose ≥ 10 mg for at least 4 weeks
Study: NCT00629473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPI-0052 on Days 1, 8, 15 every 28 days
Description: NPI-0052 dose ranging from 0.1 to 0.9 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 8, and 15 of 4-week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPI-0052 on Days 1, 4, 8, 11 every 21 days
Description: NPI-0052 dose ranging from 0.075 to 0.6 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 4, 8, and 11 of 3-week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg oral or IV day before and day after NPI-0052 dosing.
Study: NCT04384627

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Delineating the GTV according to the pretreatment or post-IC tumor extension
Description: Delineating the GTV according to the pretreatment or post-IC tumor extension
Study: NCT02090205

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non-ventilation during CPB
Description: Patients that will not be ventilated during cardio-pulmonary bypass

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilation with CPAP
Description: These patients will receive CPAP (at least 5 cmH2O and FiO2 50%-80%)
Study: NCT00622479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib will be administered at 400mg BID for a 28 day cycle.
Study: NCT03432741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Given intralesionally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given intralesionally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib Hydrochloride
Description: Given intralesionally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given intralesionally
Study: NCT02090205

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilation with 5 act/minute
Description: These patients will receive mechanical ventilation (5 acts/minute) during CPB

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Continuous Positive Air Pressure, applicated during cardio-pulmonary bypass
Study: NCT03432741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET
Study: NCT04384627

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Delineating the GTV according to the pretreatment or post-IC tumor extension
Description: Delineating the GTV according to the pretreatment or post-IC tumor extension
Study: NCT02090205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventilator: 5 act/minute
Description: Tidal volume = 2-3 ml/kg + PEEP = 3-5 cmH2O.
Study: NCT01115309

Intervention type: DEVICE
Group type: OTHER
Intervention: XprESS Balloon Device
Description: Sinus dilation completed with the XprESS Balloon Device with or without additional endoscopic sinus surgery procedures (dilation of the frontal recesses, maxillary ostia, and/or sphenoid sinus ostia).
Study: NCT03648749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech-to-noise feedback
Description: A target speech-to-noise level is specified and feedback about achievement of the target level is provided.
Study: NCT01427400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin-A
Description: 100 Units diluted in 25cc saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Dispensed in a 25cc syringe
Study: NCT04221711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive pulsed magnetic stimulation
Description: OMNITRON ProMed is a rPMS (repetitive peripheral magnetic stimulation) device used for deep stimulation of muscles and/or neurones (outside the brain). The energy is delivered by way of a special round treatment coil, whose cover material is tested for biocompatibility.~The OMNITRON ProMed device produces a high-energy impulse field and stimulates tissue, in particular soft tissue, muscles and neurons, by means of repetitive peripheral magnetic stimulation (rPMS). Short, extremely strong magnetic fields in the microsecond range are emitted non-invasively. OMNITRON ProMed works with short-term energy emission at a peak power of up to 60 million watts and a magnetic field strength of up to 100 milliTesla.~The intensity of treatment can be set between 20 and 100 %. The device automatically adjusts the magnetic field strength and the frequency of the pulses emitted depending on the intensity selected.~For comfortable transport and application the product is compact and portable.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric Calf Muscle Training for Achilles Tendinopathy
Description: Patients will be asked to stand with their full body weight on the injured leg. From an upright body position and standing with all body weight on the forefoot and the ankle joint in plantar flexion, the calf muscle is then loaded by having the patient slowly lower the heel beneath the forefoot. The calf muscle will only be loaded eccentrically, not concentric. Instead, the non-injured leg is used to get back to the start position. The first set of this exercise is performed in an upright position, followed by a second set with the knee bent to 45°. This regimen is performed 2x per day.~The patients are told to go ahead with the exercise even if they experienced pain. However, they are told to stop if the pain becomes disabling.
Study: NCT00753259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AF Clinic
Description: Treatment of atrial fibrillation patients by specialized nurses, supervised by cardiologists, using dedicated software to ensure maximal adherence to AHA/ACC/ESC guidelines on atrial fibrillation treatment
Study: NCT01086176

Intervention type: DEVICE
Intervention: NMT (a device that can do neurostimulation and can record the response on the stimulation by Datex)
Description: on one side, we do a post-tetanic count, on the other side we don't, after, we do train-of-four on both sides and check the difference
Study: NCT01422668

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Khalas dates
Description: every subject recieved 50 grams reducing carbohydrates equivalent of khalas dates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Khalas dates
Description: every subject recieved 50 grams reducing carbohydrates equivalent of khalas dates
Study: NCT04429399

Intervention type: OTHER
Group type: OTHER
Intervention: decrease the positive end expiratory pressure (PEEP)
Description: decrease the PEEP going from high (according to ExPress Trial) to low level

Intervention type: OTHER
Group type: OTHER
Intervention: mechanical features assessment
Description: evaluation of the mechanical features of respiratory system

Intervention type: OTHER
Group type: OTHER
Intervention: mechanical features assessment
Description: evaluation of the mechanical features of respiratory system

Intervention type: OTHER
Group type: OTHER
Intervention: shunt assessment
Description: evaluation of the pulmonary shunt during two different ventilation setting

Intervention type: OTHER
Group type: OTHER
Intervention: shunt assessment
Description: evaluation of the pulmonary shunt during two different ventilation setting
Study: NCT03966885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: The BI used in the trial combines motivational interviewing skills with cognitive behavioral therapy elements in order to assist clients with self identified substance misuse to begin to consider changing their rates of drinking and drug use. The intervention lasts 30 to 40 minutes and consists of 5 components including: 1) screening 2) identification and information on the impacts of substance misuse 3) talking about change and goal setting 4) understanding the primary reason for drinking 5) skill building with practice and 6) referral for services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: The BI used in the trial combines motivational interviewing skills with cognitive behavioral therapy elements in order to assist clients with self identified substance misuse to begin to consider changing their rates of drinking and drug use. The intervention lasts 30 to 40 minutes and consists of 5 components including: 1) screening 2) identification and information on the impacts of substance misuse 3) talking about change and goal setting 4) understanding the primary reason for drinking 5) skill building with practice and 6) referral for services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach (CETA)
Description: The Common Elements Treatment Approach, or CETA, is a transdiagnostic psychotherapy based on cognitive behavioral elements for mood, anxiety and trauma related problems, and for alcohol and substance misuse. CETA is based on the fact that most evidence-based mental health treatments (EBTs) consist of similar components. The objective of CETA is to provide a single training in a range of therapy components that are similar across EBTs and to then teach counselors how to design a specific course of treatment for each client based on the client's presenting problems.
Study: NCT02032407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone Gel
Description: Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.
Study: NCT03737877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet modification
Description: The parents will have four group sessions with a nutritional therapist, where in depth advice and information about the diet will be provided. Ongoing support will also be provided throughout the study by use of a closed Facebook or WhatsApp group (whichever the parents choose as most appropriate). The diet is based on five main principles:~* Eat at least seven portions of different varieties of fruit and vegetables each day.~* Have a 12 hour overnight break from food (water only during this time).~* Drink a Kefir drink each day - provided free of charge.~* Eat a microbiome friendly, protein rich, breakfast from our menu.~* Reduce sugar and artificial sweeteners.
Study: NCT03020017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted Molecular Therapy
Description: Given NU-0129 IV
Study: NCT04868149

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)
Description: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a surgical procedure that induces rapid liver regeneration in patients with small liver remnant planning for major liver resection. It is a two-staged operation with stage I including portal vein ligation and splitting the right liver away from the left liver. After stage I, the left liver will undergo rapid liver regeneration and the stage II operation can be performed at 7-10 days after stage I operation when the liver remnant reaches an adequate size. In stage II operation, the right liver that contains the tumor is then removed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)
Description: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a surgical procedure that induces rapid liver regeneration in patients with small liver remnant planning for major liver resection. It is a two-staged operation with stage I including portal vein ligation and splitting the right liver away from the left liver. After stage I, the left liver will undergo rapid liver regeneration and the stage II operation can be performed at 7-10 days after stage I operation when the liver remnant reaches an adequate size. In stage II operation, the right liver that contains the tumor is then removed.
Study: NCT03143751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl20% (Continuous hyperosmolar therapy)
Description: Early intravenous administration (\<24 hours after traumatic brain injury) of NaCl20% for a minimal duration of 48 hours (continued for as long as is necessary to prevent intracranial hypertension)~1-hour bolus (15 g if Na+ \< 145 mmol/L; 7.5 g if 145 \< Na+ \< 150 mmol/L; or no bolus) followed by 1 g/hour as long as Na+\< 150 mmol/L, reduced to 0.5 g/L if 150 \< Na+ \< 155 mmol/L, Discontinuation when 155 mmol/L\<Na+
Study: NCT04159584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Music
Description: Enrolled subjects will undergo 30 minutes of medical music listening
Study: NCT04465968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 60 mg/m2, IV, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: 80 - 120 mg/day, PO, day 1-14

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: concurrent radiotherapy
Description: 66 Gy/33 Fr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: preoperative durvalumab therapy within 28 days after chemoradiotherapy. Two courses are given every two weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery will be performed between day 15 and day 42 of the second course of preoperative durvalumab therapy after confirming that all surgical operation criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: (For resectable SST) Postoperative durvalumab therapy will be started between day 28 and day 63 with the day of surgery as Day 1. Twenty-two courses are given as a 2-week course.~Drug: Durvalumab 10 mg/kg/body, IV, day 1 (For unreectable SST) Additional durvalumab therapy between day 15 and day 28 of the second course of preoperative durvalumab therapy.~Twenty-two courses are given as 2-week course. Drug: Durvalumab 10 mg/kg/body, IV, day 1
Study: NCT00541346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Transdermal System
Description: 10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage
Study: NCT06140459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Toothbrushes
Description: Oral-B Stages 3
Study: NCT03432741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given intralesionally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given intralesionally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given intralesionally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given intralesionally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given intralesionally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Given intralesionally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Given intralesionally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given intralesionally
Study: NCT01519453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Based Asthma Education
Description: 4 home based and 3 phone based sessions with community asthma outreach worker to provide families with asthma education
Study: NCT03922451

Intervention type: DRUG
Intervention: piperacillin-tazobactam
Description: Administered for infection treatment or prophylaxis per hospital protocol

Intervention type: DRUG
Intervention: Cefazolin
Description: Administered for infection treatment or prophylaxis per hospital protocol
Study: NCT00369551

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo 3-dimensional conformal radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study: NCT06140459

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Toothbrushes
Description: Oral-B Stages 3

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsating Toothbrushes
Description: Oral-B Pulsar, Colgate 360º Micro Sonic Power
Study: NCT00369551

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02921048

Intervention type: DIETARY_SUPPLEMENT
Intervention: omega-3 fatty acids